7 April 2024
ISB 2001

Oral Presentation: ISB 2001, a BCMA and CD38 dual targeting T-cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patients relapsing from CD38 and BCMA targeted immunotherapies

Perro, M. et al.

American Association for Cancer Research Annual Meeting


 

11 Dec 2023
ISB 1442

Poster: Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Kazandjian D. et al.

American Society of Hematology Annual Meeting


 

10 Dec 2023
ISB 1342

Poster: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Kapoor P. et al.

American Society of Hematology Annual Meeting


 

10 Dec 2023
ISB 2001

Poster: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma (RRMM)

Sia H. et al.

American Society of Hematology Annual Meeting


 

5th Nov 2023
GRC 54276

Clinical Abstract: Phase 1 First In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Grc54276, A Novel HPK1 Thronine-Kinase Inhibitor, In Advanced Solid Tumours And Lymphomas.

Doddihal H. et. al.

European Hematology Association


 

22 May 2023
ISB 1342

Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple Myeloma

Perro M. et al.

Blood


 

17 Apr 2023
ISB 2001

Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell Engager

Perro M. et al.

American Association for Cancer Research Annual Meeting